课题基金 / 基金详情

项目摘要

项目成果

Rafik MARK GHOBRIAL的其他基金

相似基金

相关文献

中文摘要
翻译
这项建议的总体目标是建立一个临床研究联盟来确定ALDLT的结果。 我们提出以下具体目标,以全面评估ALDLT的影响: 1.核心研究:建立成人LDLT和非ALDLT供受者核心信息数据库 假设:ALDLT的短期生存结果,但不是并发症发生率,等同于完整身体和SLT 移植。我们和其他人,尽管接受率很高,但仍取得了良好的ALDLT短期生存结果 并发症,在非紧急患者中。为了充分评估ALDLT的好处,该技术将应用于紧急情况下的 和非紧急受者,并将其结果与三组患者队列进行比较,这三组患者包括:a)整个器官 接受者,b)身体SLT接受者,以及c)最终不接受移植的候选者。活着的捐赠者 部分将比较在世捐赠者和未接受捐赠的潜在捐赠者。主端点定义生存 供者和受者在移植后1、2和3年的结果和并发症发生率。这将澄清 ALDLT与完整身体、SLT和对照(未移植)患者在整个光谱中的疗效比较 受者的状态,并确定与非移植的非移植的自然病史相比,ALDLT是否合理 紧急控制。次要终点评估技术变化对术后恢复、肝脏的影响 捐献后再生,活体捐献对身体捐赠者池的影响,并界定捐赠者排除标准。 2.受者结局的临床研究方案:确定ALDLT对移植后丙型肝炎复发的影响 在移植受者假说中:ALDLT可能伴随着丙型肝炎加速复发而不是整个 身体肝移植。在我们中心观察到的ALDLT受者中快速和严重的丙型肝炎复发 对于整个器官移植患者来说,可能会抵消活体捐赠者早期移植的好处。该协议 比较ALDLT和全器官移植受者6个月、1个月、2个月和3个月丙型肝炎复发的组织学时间 移植后数年。肝移植对人和移植物存活的影响及组织学程度的相关性 疾病和丙型肝炎病毒RNA水平由我们的次要终端进行调查。 3.捐赠者结局的临床研究方案:确定与健康相关的生活质量结局和资源 成人活体捐献假说的应用:活体捐赠者的HRQL在短期内受到影响,但在长期和 ALDLT后受者的HRQL可能得到提高。将比较捐赠者和受赠者的HRQL 在ALDLT前以及移植后6个月和12个月通过通用和疾病特异性仪器进行治疗。另外, 开展卫生效用指数评估和卫生资源利用评价。
英文摘要
The overall objective of this proposal is to establish a Clinical Research Consortium to define the outcomes of ALDLT. We propose the following specific aims to fully evaluate the impact of ALDLT: 1. Core Study: Establish a Donor and Recipient Core Information Database for Adult LDLT and Non-ALDLT Patients Hypothesis: ALDLT short-term survival outcomes, but not complication rates, are equivalent to whole cadaveric and SLT transplantation. We and others, achieved excellent short-tern survival outcomes of ALDLT, despite a high rate of recipient complications, in non-urgent patients. To fully evaluate the benefits of ALDLT, the technique will be applied to both urgent and non-urgent recipients, and compare its outcomes to three sets of patient cohorts that include: a) whole organ recipients, b) cadaveric SLT recipients, and c) candidates who ultimately do not receive a transplant. The living donor section will compare living donors and potential donors who do not undergo donation. Primary endpoints define survival outcomes and complication rates in donors and recipients at 1, 2 and 3 years posttransplantation. This will elucidate the efficacy of ALDLT as compared to whole cadaveric, SLT, and control (untransplanted) patients in the entire spectrum of recipients' status, and determine if ALDLT is justified when compared to the natural history of non-transplanted non- urgent controls. Secondary endpoints assess the impact of technical variations on postoperative recovery, liver regeneration postdonation, impact of living donation on the cadaveric donor pool, and defines donor exclusion criteria. 2. Clinical Research Protocol for Recipient Outcome: Determine the impact of ALDLT on Posttransplant HCV Recurrence in Transplant Recipients Hypothesis: ALDLT may be accompanied by accelerated recurrence of HCV versus whole cadaveric liver transplantation. Rapid and severe HCV recurrence observed, at our center, in ALDLT recipients compared to whole organ transplant patients, may offset the benefits of early transplantation with living donors. This protocol compares the time to histological recurrence of HCV in ALDLT and whole organ graft recipients at 6 months, 1, 2, and 3 years posttransplantation. The effects on patient and graft survival and the correlation between the degree of histological disease and HCV RNA levels are investigated by our secondary endpoints. 3. Clinical Research Protocol for Donor Outcome: Determine Health-Related Quality of Life Outcomes and Resource Utilization of Adult Living Donation Hypothesis: HRQL of living donors is impacted in the short-, but not, the long-term and the HRQL of ALDLT recipients may be enhanced following ALDLT. HRQL in both donors and recipients will be compared before ALDLT and at 6 and 12 months posttransplantation through generic and disease-specific instruments. Additionally, health utility index assessments and evaluation of health care resource utilization will be conducted.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
4/4-American Consortium of Early Liver Transplantation-Prospective Alcohol-associated liver disease Cohort Evaluation (ACCELERATE-PACE)
TRANSPLANT IMMUNOMODULATION BY ALLOCHIMERIC MOLECULES
TRANSPLANT IMMUNOMODULATION BY ALLOCHIMERIC MOLECULES
TRANSPLANT IMMUNOMODULATION BY ALLOCHIMERIC MOLECULES
海外基金